<DOC>
	<DOC>NCT00334646</DOC>
	<brief_summary>This study is designed to evaluate the potential pharmacokinetic interaction between oral GW679769 and IV (intravenous) cyclophosphamide when administered to cancer patients.</brief_summary>
	<brief_title>Cyclophosphamide Drug Interaction Study In Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Casopitant</mesh_term>
	<criteria>Histologically or cytologically confirmed diagnosis of cancer. Undergoing chemotherapy with a cyclophosphamide regimen with a cyclophosphamide dose of 500 700 mg/m2 and a cycle duration of 1428 days. Adequate hematologic, renal and hepatic function. Pregnant or lactating. CNS (central nervous system) metastases. Active systemic infection or any other poorly controlled medical condition. Patients cannot take CYP3A4 inhibitors within 7 days of study treatment or CYP3A4 inducers within 48 days of study treatment.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>cyclophosphamide</keyword>
	<keyword>CINV</keyword>
	<keyword>Chemotherapy induced nausea and vomiting</keyword>
</DOC>